MAP2K1 and astrocytic tumor: Selumetinib is a highly potent and selective non-ATP-competitive MEK1/2 inhibitor30, and the results from the National Cancer Institute showed a good therapeutic effect31 in a clinical trial of selumetinib in the treatment of low-grade astroglioma and metastatic low-grade glioma (NCT04166409) conducted on January 3, 2020.